2021
Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Moutafi M, Koliou G, Papaxoinis G, Gavrielatou N, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Fernandez A, Yaghoobi V, Shafi S, Vathiotis I, Aung T, Gkolfinopoulos S, Foukas P, Fountzilas G, Rimm D. Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6064-6064. DOI: 10.1200/jco.2021.39.15_suppl.6064.Peer-Reviewed Original ResearchCombined positive scorePD-L1 expressionQuantitative immunofluorescencePD-L1Preclinical modelsCD8 T cell infiltrationNeck squamous cell carcinomaPhase II trialReal-time quantitative reverse transcription polymerase chain reactionT cell infiltrationPD-L1 upregulationSquamous cell carcinomaPD-L1 mRNAQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionBiomarker groupsWindow studyTranscription-polymerase chain reactionSTING protein levelsPost-treatment samplesII trialAntitumor immunityImmune infiltratesPD-1Dual blockade
2011
S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome.
Bianchini G, Pusztai L, Iwamoto T, Kelly C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. DOI: 10.1158/0008-5472.sabcs11-s1-7.Peer-Reviewed Original ResearchDistant relapse ratesPatterns of relapseAromatase inhibitorsLate relapseRelapse rateHigh riskTime cohortsEstrogen receptor-positive casesOncotype DX recurrence scoreAdjuvant clinical trialsEndocrine-sensitive cancersEndocrine-sensitive tumorsLow-proliferation tumorYears of tamoxifenNode-negative tumorsReceptor-positive casesUse of tamoxifenDX recurrence scoreBiomarker groupsEndocrine therapyEndocrine drugsEarly relapseEndocrine resistanceLate recurrenceRisk stratification
2010
Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers
Justice A, McGinnis K, Skanderson M, Chang C, Gibert C, Goetz M, Rimland D, Rodriguez‐Barradas M, Oursler K, Brown, Braithwaite R, May M, Covinsky K, Roberts, Fultz S, Bryant K, Team F. Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers. HIV Medicine 2010, 11: 143-151. PMID: 19751364, PMCID: PMC3077949, DOI: 10.1111/j.1468-1293.2009.00757.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsBiomarkersCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionDrug Therapy, CombinationFemaleHepatitis, Viral, HumanHIV InfectionsHIV Long-Term SurvivorsHumansLiver CirrhosisMaleMiddle AgedRNA, ViralSeverity of Illness IndexSubstance-Related DisordersSurvival AnalysisConceptsCombination antiretroviral therapyVeterans Aging Cohort StudyHIV biomarkersVACS IndexHIV infectionSurvival intervalAging Cohort StudyShorter survival intervalAntiretroviral therapyCause mortalityCohort studyHIV markersPrognostic indexAIDS conditionsChronic inflammationMortality riskHIVSubstance abuseBiomarkersMortalityBiomarker groupsComplete dataSimilar intervalsInfectionFurther validation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply